Coherus BioSciences, Inc. (CHRS) Dividend History

Company News

• Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes

  Coherus BioSciences announced it will repurchase $170 million of its convertible notes and divest its UDENYCA franchise to Intas Pharmaceuticals. The company plans to repurchase the remaining $60 million of convertible notes after the divestiture closes.

  GlobeNewswire Inc.
• Hepatic Tumor Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ Companies Working in the Domain

  The hepatic tumor market is driven by the increasing incidence of liver cancer, advancements in treatment options, and the growing emphasis on personalized medicine and combination therapies. The pipeline comprises 75+ companies working on 75+ pipeline therapies, with several promising candidates in different phases of clinical trials.

  GlobeNewswire Inc.
• Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

  – Transaction aligns with Coherus’ strategic focus on oncology – – Transaction aligns with Coherus’ strategic focus on oncology –

  GlobeNewswire Inc.
• Pfizer: Seriously Undervalued At Peak Pessimism

  Pfizer's impressive financial results and promising clinical trials make it an undervalued asset in the pharmaceutical industry.

  Seeking Alpha

  Featured Companies: ABBV BMY JNJ MRK PFE
• Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

  CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors

  GlobeNewswire Inc.